STAT March 14, 2024
Rachel Cohrs

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma / Biotech, Physician, Provider
109 hospitals receiving new Medicare-backed residency slots
Senators urge Congress to avert Medicare physician pay cut
Podcast: Medicare Shared Savings Program Mints $2B Win for Value-Based Care w/ Frank McStay
Medicare Part D in 2025: A First Look at Prescription Drug Plan Availability, Premiums, and Cost Sharing
Dr. Oz, RFK Jr. on Medicare, Medicaid: 10 notes

Share This Article